Impact of tafamidis on myocardial function and CMR tissue characteristics in transthyretin amyloid cardiomyopathy

• DOI: 10.1002/ehf2.14815
• Publication Date: 2024-05-13T03:45:40Z
• Authors: Stephan Dobner; Benedikt Bernhard; Lorenz Ninck; Monika Wieser; Adam Bakula; Andreas Wahl; Valentin Köchli; Giancarlo Spano; Martina Boscolo B...; Elena Elchinova; Yasaman Safarkhanlo; Stefan Stortecky; Jonathan Schütze; Isaac Shiri; Lukas Hunziker; Christoph Gräni
• Keywords: Male; GLS; Benzoxazoles; Amyloid Neuropathies, Familial; Heart Ventricles; Myocardium; Magnetic Resonance Imaging, Cine; 610 Medicine & health; Stroke Volume; Cardiac amyloidosis; ECV; Tafamidis; Ventricular Function, Left; Feature tracking; RC666-701; Diseases of the circulatory (Cardiovascular) system; Humans; Original Article; Female; Prospective Studies; Cardiomyopathies; Cardiac magnetic resonance imaging; Aged; Follow-Up Studies

Tafamidis improves clinical outcomes in transthyretin amyloid cardiomyopathy (ATTR-CM), yet how tafamidis affects cardiac structure and function remains poorly described. This study prospectively analysed the effect of on 12-month longitudinal changes by magnetic resonance (CMR) compared with natural course disease an untreated historic control cohort.